Monoclonal antibody · Antagonist of signal-regulatory protein (SIRP) (SIRPA) · developed by Electra Therapeutics
Ipsoprubart is a human IgG1 monoclonal antibody targeting signal-regulatory protein (SIRP) expressed on myeloid cells and T-lymphocytes. It depletes pathological immune cells driving excessive inflammation. The drug is studied in secondary hemophagocytic lymphohistiocytosis.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05416307 | Phase 2/3 | Secondary Hemophagocytic Lymphohistiocytosis (sHLH) | Recruiting | ETRA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
See ETRA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ETRA catalysts and pipeline →